StreetAlpha.app
Home › Stocks › VSTM

Verastem, Inc. (VSTM)

Healthcare
$7.41
▼ −3.77%
LAST CLOSE · NOV 17

Verastem develops and markets cancer medicines that target the RAS/MAPK pathway, including an approved ovarian cancer treatment. It last closed at $7.41 on Nov 17, down 3.77% on the day. The average 12-month price target from 4 analysts is $18.75 (+153.0% from the last close), with a high of $24.00 and a low of $13.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in VSTM, 0% of them bullish and 100% bearish. In the past 30 days there were 3 dark pool prints totaling $1.3M, the largest $513K.

AI Auto Pilots
Is VSTM in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$100.3M
Net income
−$178.9M
−178.4% margin
EPS (diluted)
−$1.84
Operating margin
−193.7%
−$194.3M operating income
Valuation
Market cap
$933.8M
126.0M shares
P/E
–
No P/E while losing money
Price to sales
9.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$172.8M
At Sep 30
Shareholder equity
$10.1M
Shares outstanding
126.0M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $2.1M$2.1MFY2021FY2022: $2.6M$2.6MFY2022FY2024: $10.0M$10.0MFY2024FY2025: $30.9M$30.9MFY2025

From VSTM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on VSTM in the past 90 days
Average 12-month target
$18.75
▲ 153.0% upside

Based on 4 analysts who set a price target on VSTM in the past 90 days. The average target is $18.75, with a high of $24.00 and a low of $13.00, compared with the last close of $7.41.

Low $13.00Avg $18.75High $24.00
Blue marker: last close $7.41
Highest target$24.00
Average target$18.75
Lowest target$13.00
Latest rating changes
RBC CapitalTarget lowered
Nov 6Buy$19 → $18
HC Wainwright & Co.Maintained
Nov 6Buy$20
BTIGReiterated
Oct 19Buy$24
JefferiesTarget raised
Oct 15Buy$8 → $13
RBC CapitalTarget raised
Oct 15Buy$14 → $19
DateFirmActionRatingPrice target
Nov 6RBC CapitalTarget loweredBuy$19 → $18
Nov 6HC Wainwright & Co.MaintainedBuy$20
Oct 19BTIGReiteratedBuy$24
Oct 15JefferiesTarget raisedBuy$8 → $13
Oct 15RBC CapitalTarget raisedBuy$14 → $19
Loading…

Technical Analysis

VSTM · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold

The stock is 24% below its 20 day and 14% below its 50 day average. It is 15% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 35), near oversold. The nearest support is the swing low (Sep 28) at $7.39, and the nearest resistance the Pivot at $7.55.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 8.7%/day
Key levels
$10.8252 week high+46.0%
$9.2020 day average+24.2%
$8.4650 day average+14.2%
$7.86Swing high (Aug 19)+6.1%
$7.74Pivot R1+4.5%
$7.55Pivot+1.9%
$7.41Last close
$7.39Swing low (Sep 28)−0.3%
$7.36100 day average−0.7%
$7.22Pivot S1−2.6%
$6.31200 day average−14.8%
$3.4352 week low−53.7%
Indicators
RSI (14)35.08Weak, oversold below 30Neutral
MACD-0.18Below its signal lineBearish
Stochastic6.5Near the bottom of its rangeOversold
ADX (14)29.4Trending down
Williams %R-98.0Oversold below −80, overbought above −20Oversold
CCI (20)-164.9Oversold below −100, overbought above 100Oversold
Rate of change−24.2%Change over 10 sessionsBearish
ATR (14)$0.64Typical daily range, 8.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for VSTM

What happened before

See how VSTM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow VSTM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How VSTM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
0
0%
Bearish
1
100%
Date span
Aug 25 – Aug 25
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$1.3M
Largest print
$513K
Loading…

VSTM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲94 buying vs 73 selling
  • ▼Held by funds -8.4 pts
  • ▲Funds holding +4
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding162158+2.5%
In funds' top 1052+150.0%
Held by funds70.1%78.5%−8.4 pts
New / increased35 / 5933 / 70−8.7%
Reduced / sold out44 / 2934 / 28+17.7%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VSTM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VSTM is in one of them and how their past VSTM trades turned out.

VSTM in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VSTM in an article yet. Here's the latest on the wider market.

About Verastem

Verastem is a biopharmaceutical company based in Needham, Massachusetts, that develops and sells medicines for cancers driven by the RAS/MAPK pathway. Its approved product, AVMAPKI FAKZYNJA CO-PACK, is marketed in the United States to adults with recurrent low grade serous ovarian cancer that has KRAS mutations and who have had prior systemic therapy. Its pipeline includes VS-7375, an oral KRAS G12D inhibitor being studied in pancreatic, lung and colorectal cancers. Its customers are cancer patients and the physicians who treat them.

Headquarters
Needham, MA